Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
34
Recruiting, any sponsor type, condition "urticaria"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed257
34 trials
Showing 1 to 25, recently updated first.
- A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible UrticariaRecruiting
Granular Therapeutics LimitedIndustry
NCT07181369 · 72 participants (planned) · Start Oct 6, 2025 · Primary completion Aug 2027
Drug: GTX-B001; Normal Saline · For: Healthy Subjects; Cold Urticaria; Symptomatic Dermographism and 1 more
Sites: Berlin, Germany; Halle, Germany; Marburg, Germany · 6 sites in all
- Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema AttacksPivotal-lookingRecruiting
OctapharmaIndustry
NCT06361537 · 124 participants (planned) · Start Apr 30, 2024 · Primary completion Dec 2026
Drug: OCTA-C1-INH · For: Acute Hereditary Angio Edema
Sites: Centennial, Colorado; Farmington Hills, Michigan; Toledo, Ohio · 29 sites in all
Novelty Nobility, Inc.Industry
NCT07930572 · 46 participants (planned) · Start Oct 15, 2026 · Primary completion Mar 31, 2027
Drug: NN2802 · For: Healhty; Chronic Spontaneous Urticaria (CSU)
Sites: Hangzhou, China
- Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 WeeksPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07816328 · 382 participants (planned) · Start Sep 21, 2026 · Primary completion May 24, 2028
Drug: Remibrutinib; Omalizumab · For: Chronic Spontaneous Urticaria
Sites: London, Canada; Québec, Canada; Hong Kong, Hong Kong · 10 sites in all
- A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)Pivotal-lookingRecruiting
Celldex TherapeuticsIndustry
NCT07266402 · 240 participants (planned) · Start Jan 15, 2026 · Primary completion Jun 2028
Drug: Barzolvolimab; Matching Placebo · For: Chronic Inducible Urticaria; Cold Urticaria; Cold-Induced Urticaria and 1 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Bakersfield, California · 72 sites in all
- Donidalorsen Treatment in Children With Hereditary AngioedemaPivotal-lookingRecruiting
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT07298447 · 20 participants (planned) · Start Apr 21, 2026 · Primary completion Jun 2029
Drug: Donidalorsen · For: Hereditary Angioedema (HAE)
Sites: Santa Monica, California; Miami, Florida; Baton Rouge, Louisiana · 18 sites in all
Calixis Inc.Industry
NCT07766499 · 81 participants (planned) · Start Sep 15, 2026 · Primary completion Dec 31, 2027
Drug: THB335 Lower Dose; THB335 Higher Dose and 1 more · For: Chronic Spontaneous Urticaria (CSU); Chronic Idiopathic Urticaria
Sites: Pasadena, California; Ventura, California; Walnut Creek, California · 15 sites in all
- A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07219615 · 200 participants (planned) · Start Oct 30, 2025 · Primary completion Dec 25, 2026
Drug: Ritlecitinib 50 mg; Ritlecitinib 100 mg and 2 more · For: Chronic Spontaneous Urticaria
Sites: Phoenix, Arizona; Little Rock, Arkansas; Bakersfield, California · 77 sites in all
- Comparing Standard-Dose and High-Dose Cetirizine for Acute UrticariaPivotal-lookingRecruiting
University of PhayaoAcademic, hospital or other
NCT07236372 · 140 participants (planned) · Start Nov 15, 2025 · Primary completion Mar 2027
Drug: Cetirizine 10 mg once daily; Cetirizine 20 mg twice daily, total 40 mg/day · For: Acute Urticaria
Sites: Phayao, Thailand
Novartis PharmaceuticalsNovartis (NVS)
NCT06865651 · 44 participants (planned) · Start May 22, 2025 · Primary completion Aug 23, 2027
Drug: Remibrutinib; Placebo · For: Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
Sites: North Miami Beach, Florida; Glenview, Illinois; Grenoble, France · 17 sites in all
Centre Hospitalier Universitaire de BesanconAcademic, hospital or other
NCT07833696 · 73 participants (planned) · Start Jan 1, 2020 · Primary completion Dec 31, 2026
Drug: drug effect · For: Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
Sites: Besançon, France
- Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor DeficiencyPivotal-lookingRecruiting
Pharvaris Netherlands B.V.Industry
NCT07266805 · 48 participants (planned) · Start Oct 16, 2025 · Primary completion Jun 2027
Drug: Deucrictibant; Placebo and 3 more · For: Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
Sites: San Diego, California; Walnut Creek, California; St Louis, Missouri · 32 sites in all
KalVista Pharmaceuticals, Ltd.Industry
NCT07654829 · 100 participants (planned) · Start Aug 17, 2026 · Primary completion Nov 29, 2027
Drug: KVD900 600 mg · For: Hereditary Angioedema
Sites: Colorado Springs, Colorado
- An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous UrticariaRecruiting
ARS Pharmaceuticals, Inc.Industry
NCT06927999 · 42 participants (planned) · Start Jul 9, 2025 · Primary completion Jun 2027
Drug: Placebo; 0.5 mg epinephrine and 1 more · For: Urticaria Chronic
Sites: Glenview, Illinois; Cincinnati, Ohio; Berlin, Germany
Cogent Biosciences, Inc.Industry
NCT04996875 · 140 participants (planned) · Start Nov 9, 2021 · Primary completion Sep 19, 2025
Drug: bezuclastinib · For: Advanced Systemic Mastocytosis (AdvSM); SM With an Associated Hematologic Neoplasm (SM-AHN); Mast Cell Leukemia (MCL) and 1 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Duarte, California · 42 sites in all
- STOP-HAE: A Phase 3 Study of ADX-324 in HAEPivotal-lookingRecruiting
ADARx Pharmaceuticals, Inc.Industry
NCT06960213 · 90 participants (planned) · Start Aug 28, 2025 · Primary completion Nov 30, 2027
Drug: ADX-324; Placebo · For: Hereditary Angioedema; HAE; Hereditary Angioedema - Type 1 and 1 more
Sites: Litchfield Park, Arizona; Scottsdale, Arizona; Little Rock, Arkansas · 70 sites in all
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT07005713 · 58 participants (planned) · Start Jul 19, 2025 · Primary completion Nov 30, 2026
Drug: Tacabrutideg; Placebo · For: Chronic Spontaneous Urticaria
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 9 sites in all
- Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)Pivotal-lookingRecruiting
ADARx Pharmaceuticals, Inc.Industry
NCT07428499 · 90 participants (planned) · Start Apr 2, 2026 · Primary completion Jun 30, 2030
Drug: ADX-324 Dose Level 1; ADX-324 Dose Level 2 · For: Hereditary Angioedema (HAE); Hereditary Angioedema - Type 1; Hereditary Angioedema - Type 2 and 1 more
Sites: Litchfield Park, Arizona; Little Rock, Arkansas; San Diego, California · 48 sites in all
- Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.Pivotal-lookingRecruiting
JemincareIndustry
NCT07402213 · 240 participants (planned) · Start Mar 9, 2026 · Primary completion Jun 7, 2027
Drug: JYB1904; Placebo+JYB1904 · For: Chronic Spontaneous Urticaria
Sites: Beijing, China
Bambusa TherapeuticsIndustry
NCT07717905 · 48 participants (planned) · Start Jun 29, 2026 · Primary completion Dec 31, 2027
Drug: BBT001; Placebo · For: Chronic Spontaneous Urticaria
Sites: Wuhu, China; Beijing, China; Guangzhou, China · 10 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT06974877 · 30 participants (planned) · Start Sep 10, 2025 · Primary completion Jul 1, 2031
Drug: 124I AT-01 · For: Cryopyrin-Associated Periodic Syndromes; Amyloidosis
Sites: Bethesda, Maryland
- Ilaris NIS in KoreaRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06838143 · 25 participants (planned) · Start Mar 29, 2025 · Primary completion Sep 30, 2028
Drug: Ilaris · For: Hereditary Periodic Fever Syndromes; Cryopyrin-associated Periodic Syndromes (CAPS); Colchicine Resistance Familial Mediterranean Fever (crFMF) and 3 more
Sites: Seoul, South Korea
Enanta Pharmaceuticals, IncIndustry
NCT07540910 · 98 participants (planned) · Start Apr 1, 2026 · Primary completion Nov 2026
Drug: EDP-978; Placebo · For: Chronic Inducible Urticaria; Chronic Spontaneous Urticaria
Sites: San Antonio, Texas
- Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous UrticariaPivotal-lookingRecruiting
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT07378527 · 344 participants (planned) · Start Feb 13, 2026 · Primary completion Sep 2028
Drug: ICP-332 Tablets; ICP-332 placebo Tablets and 1 more · For: Chronic Spontaneous Urticaria (CSU)
Sites: Bengbu, China; Wuhu, China; Beijing, China · 30 sites in all
- Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-AntihistaminesPivotal-lookingRecruiting
Yuhan CorporationIndustry
NCT07415551 · 150 participants (planned) · Start Mar 26, 2026 · Primary completion Jun 19, 2027
Drug: Lesigercept; Placebo · For: Allergic Diseases; Chronic Spontaneous Urticaria (CSU)
Sites: Sofia, Bulgaria; Guangzhou, China; Shenzhen, China · 30 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.